Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.35 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.35 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29152863 | 0.73 | RAD52 (0.49) | RAD52CDK2CCNE1HTR1DHTR3A | |
| SCHEMBL2964886 | 0.73 | NPC1 (0.47) | MAPK8BTKMRGPRX2ALDH1A1MEN1 | |
| SCHEMBL868954 | 0.72 | KDM4E (0.49) | ALDH1A1 | |
| SCHEMBL1487823 | 0.72 | PDE10A (0.39) | RAD52CDK2CCNE1KCNN3PDE10A | |
| SCHEMBL15690546 | 0.72 | PDE10A (0.39) | CDK2CCNE1MAPK8PDE10APIM1 | |
| SCHEMBL2968218 | 0.70 | PDE10A (0.42) | RAD52CDK2CCNE1HTR1DHTR3A | |
| SCHEMBL13225458 | 0.69 | PDE10A (0.41) | CDK2HTR1DHTR3AHTR6TMEM97 | |
| SCHEMBL5239519 | 0.68 | PDE10A (0.38) | CDK2CCNE1KCNN3PDE10APDE4B | |
| SCHEMBL14013818 | 0.68 | PDE10A (0.39) | KCNN3KCNN1KCNN2PDE10APIM1 | |
| SCHEMBL17966386 | 0.68 | ALDH1A1 (0.55) | RAD52CDK2CCNE1HTR1DHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20130317002-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | US | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2188291-A2 | FUSED BICYCLIC PYRIMIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2050748-A1 | Novel fused pyrimidines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009021992-A2 | FUSED BICYCLIC PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | RAD52 1690/4885CDK2 8/4885CCNE1 161/4885 |
| US-20130317002-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, TYMS | RAD52 2542/4885CDK2 19/4885CCNE1 191/4885 |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | RAD52 1690/4885CDK2 8/4885CCNE1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.